ClinicalTrials.gg
RecruitingNCT07068529Updated Jul 16, 2025

Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC

An observational study in Colorectal Cancer, sponsored by Shanghai Minimally Invasive Surgery Center. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Shanghai Minimally Invasive Surgery Center · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
148th of 243
250 · median 400
Started
2025
with 124 others
Observational
243 of 1,139
92 open now
Primary completion
2028-07
later than 509 of 605 live
Registered
932nd of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 148th largest by planned enrollment of the 243 observational ones that give a count, is one of 125 that started in 2025, is one of 243 observational ones, reaches primary completion later than 509 of the 605 other live ones, and was the 932nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This prospective clinical observational study aims to construct a metabolite database specifically for colorectal cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in colorectal cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Metabolic Marker
  • Prognosis
  • Early Diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with colorectal cancer and healthy individuals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • **Healthy Controls:**

    1. Age ≥ 18 years;
    2. Signed and willingness to participate in the project.

**Colorectal Cancer:**

  1. Age ≥ 18 years;
  2. Performance status () score ≤ 1;
  3. Histopathologically confirmed colorectal adenocarcinoma;
  4. No family history of hereditary cancer;
  5. No prior anti-tumor treatment;
  6. Availability of primary tumor tissue from surgery or that meets submission requirements;
  7. Availability of peripheral blood samples that meet submission requirements;
  8. Willingness and ability to sign the informed consent form to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • **Healthy Controls:**

    1. Individuals at high risk for hereditary colorectal adenocarcinoma, including family members of the following diseases: family history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC/LS), and Peutz-Jeghers syndrome (P-J syndrome);
    2. History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
    3. Known history of other that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
    4. History of oral or intravenous use of broad-spectrum antibiotics and probiotics within the past month;
    5. Regular use of drugs within the past 6 months;
    6. Long-term use of other medications that may affect metabolism, such as hormones;
    7. Inability or unwillingness to cooperate with follow-up visits and related examinations;
    8. Inability to eat normally or requiring medications or enemas for bowel movements;
    9. Presence of psychiatric disorders or other severe cardiovascular diseases;
    10. Pregnant, breastfeeding, or planning to become pregnant within the next year;
    11. Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision.

**Colorectal Cancer:**

  1. A clear family history of hereditary colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, etc.;
  2. Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision;
  3. Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
  4. History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
  5. Presence of poorly controlled chronic comorbidities that may affect prognosis;
  6. Presence of psychiatric disorders or other severe cardiovascular diseases;
  7. Pregnant, breastfeeding, or planning to become pregnant within the next year;
  8. Long-term use of medications that may affect metabolism, such as hormones, immunosuppressants, antibiotics, etc.;
  9. Any severe and/or uncontrolled medical conditions, as judged by the investigator, that may affect the patient's ability to participate in the study or interfere with study results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Baseline

    This group recruits healthy individuals which is intended to establish a metabolic biomarker baseline

  • CRC

    Colorectal cancer group, which is study of interest

06

What researchers measure

Primary outcomes

  1. Overall survival

    The time from the start of treatment to death due to any cause.

    Time frame: 3 years

  2. Disease-Free Survival

    Disease-Free Survival (DFS) refers to the length of time after primary treatment for a disease during which the patient remains free of certain signs or symptoms of the disease. It is typically measured from the start of treatment until the first recurrence or relapse of the disease.

    Time frame: 3 years

Secondary outcomes

  1. Hazard Ratio

    The hazard ratio is a measure of the relative risk of an event occurring in one group compared to another group. It is used to quantify the difference in the rate at which events occur between two groups, typically a treatment group and a control group.

    Time frame: 3 years

  2. Positive Predictive Value

    The Positive Predictive Value (PPV) indicates how likely it is that a person actually has the disease if the test result is positive.

    Time frame: 3 years

  3. Negative Predictive Value

    The Negative Predictive Value (NPV) indicates how likely it is that a person does not have the disease if the test result is negative.

    Time frame: 3 years

  4. Assessment of Important Metabolic Biomarkers

    Time frame: 3 years

  5. Recurrence and Metastasis Rate

    Time frame: 3 years

  6. Cancer-Related Mortality

    Time frame: 3 years

  7. Time to Recurrence and Metastasis and Specific Sites

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 36 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Jun 15, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2030
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068529
Lead sponsor
Shanghai Minimally Invasive Surgery Center
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Jun 15, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Jul 16, 2025

Study contacts

Jing Sun
Contact
sj117788@rjh.com.cn
+86-13524284622

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion